Stapokibart improves sleep quality in patients with chronic rhinosinusitis with nasal polyps
In a post hoc analysis of the phase 3 CROWNS-2 study, stapokibart significantly improved SNOT-22 Sleep domain scores compared with placebo during the 24-week double-blind period. These improvements were maintained and further progressed during the open-label extension and safety follow-up periods, indicating sustained benefit for sleep quality.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Stapokibart improves sleep quality in patients with chronic rhinosinusitis with nasal polyps The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
Stapokibart improves sleep quality in patients with chronic rhinosinusitis with nasal polyps
This conclusion is most relevant to: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸[Quality of life improvement with stapokibart in chronic rhinosinusitis with nasal polyps: a post hoc analysis of phase 3 CROWNS-2 study]. (Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery, 2026) —
How It Works
The proposed biological pathway:
- ▸Stapokibart binds to IL-4 receptor α subunit
- ▸Blocks IL-4 and IL-13 signaling pathways
- ▸Reduces type 2 inflammation in nasal and sinus mucosa
- ▸Improves sinonasal symptoms including sleep disturbance
Who Might Benefit
Evidence fit by population:
- ▸Patients with chronic rhinosinusitis with nasal polyps (CRSwNP)
Recommended Dose
300 mg every 2 weeks
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Post hoc analysis, not pre-specified primary endpoint
- ▸No specific sleep quality metrics beyond SNOT-22 domain score
- ▸Limited generalizability due to single study design
Frequently Asked Questions
What is stapokibart?▼
Stapokibart is an anti-interleukin-4 receptor α monoclonal antibody that blocks IL-4 and IL-13 signaling pathways, used for treating chronic rhinosinusitis with nasal polyps.
How was sleep quality measured in this study?▼
Sleep quality was measured using the Sleep domain of the 22-item Sinonasal Outcome Test (SNOT-22), a validated patient-reported outcome instrument.
How long did the sleep improvements last?▼
Sleep improvements were maintained and further progressed during the 28-week open-label extension and subsequent 8-week safety follow-up period.
What is the CROWNS-2 study?▼
CROWNS-2 is a phase 3 randomized controlled trial evaluating stapokibart versus placebo in patients with chronic rhinosinusitis with nasal polyps, with a 24-week double-blind period followed by open-label extension.
References
- 1.Yan B, Jin Z, Zhang L, Wang C. “[Quality of life improvement with stapokibart in chronic rhinosinusitis with nasal polyps: a post hoc analysis of phase 3 CROWNS-2 study]..” Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery, 2026. PMID: 42402685 DOI: 10.13201/j.issn.2096-7993.2026.07.010